English
Back
Download
Log in to access Online Inquiry
Back to the Top

UPDATES

$Biomea Fusion (BMEA.US)$ Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
4817 Views
Comment
Sign in to post a comment
    198
    Followers
    37
    Following
    841
    Visitors
    Follow